USPTO serial 79052271
Serial No. 79052271
Reviewed by CopyMark Law Group
Reg. 3502080Status 706Registered
- Filing date
- Status date
- Registration date
- Sep 16, 2008
- Examiner
- BUNCH, TASHIA AUNGELIK
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with Serial No. 79052271?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
DK-1253 København K, DK
DK-1253 København K, DK
DK
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Max Vern
Max Vern AMSTER, ROTHSTEIN & EBENSTEIN LLP405 Lexington AvenueNew York, NY 10174United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical, namely, monoclonal antibodies for in vivo or in vitro scientific research and in vivo or in vitro development in the field of cancer [, AIDS, acquired immune deficiency syndrome, ] and other infectious diseases, immune and autoimmune diseases, inflammatory diseases [ and cardiovascular diseases ] | ACTIVE | — |
| 005 | Pharmaceutical preparations based on human monoclonal antibodies for use in the treatment of cancer [, AIDS, acquired immune deficiency syndrome, ] and other infectious diseases, immune and autoimmune diseases, inflammatory diseases [ and cardiovascular diseases ] | ACTIVE | — |
| 042 | Medical scientific research, namely, biological research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for use in the treatment of cancer, AIDS, acquired immune deficiency syndrome, and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases; chemical analysis, patent exploitation, licensing of intellectual property in the field of medicine; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy with monoclonal antibodies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 24, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 5, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 5, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 5, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 5, 2024 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Jun 5, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 5, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 5, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 19, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Feb 21, 2020 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Jan 3, 2020 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jan 3, 2020 | INPC | INVALIDATION PROCESSED | — |
| Dec 2, 2019 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 2, 2019 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 2, 2019 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Mar 15, 2019 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Oct 26, 2017 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 16, 2017 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Sep 8, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 20, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 9, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 9, 2017 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 11, 2015 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Mar 20, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 7, 2014 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Aug 7, 2014 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Aug 7, 2014 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 18, 2014 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 15, 2010 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 16, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 1, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| May 29, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 28, 2008 | ALIE | ASSIGNED TO LIE | — |
| May 28, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| May 12, 2008 | NWAP | NEW APPLICATION ENTERED | — |
| May 9, 2008 | LIMS | LIMITATION OF GOODS/SERVICES FROM IB ENTERED | — |
| May 8, 2008 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |